Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
December 09, 2024 19:30 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
December 02, 2024 07:00 ET
|
Autolus Therapeutics plc
High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity:...
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 12, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Third Quarter 2024 Financial Results
and Business Updates
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
November 08, 2024 16:23 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
November 05, 2024 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
October 28, 2024 17:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
October 16, 2024 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
September 19, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
August 27, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus presents clinical data update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
June 14, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Three Clinical Data Updates on obe-cel at EHA